Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment.
about
From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumorsThe use of immunotherapy in the treatment of melanomaDormancy of metastatic melanomaPD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence.STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.Immune checkpoint blockade and interferon-α in melanoma.Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype.Cancer immunotherapy: Progress and challenges in the clinical setting.Immunotherapy of cancer in 2012.Statins stimulate in vitro membrane FasL expression and lymphocyte apoptosis through RhoA/ROCK pathway in murine melanoma cells.Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination.Targeting Ornithine Decarboxylase by α-Difluoromethylornithine Inhibits Tumor Growth by Impairing Myeloid-Derived Suppressor CellsSystemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growthMicro-proteome analysis using micro-chromatofocusing in intact protein separations.Cancer stem cells and human malignant melanomaCD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential.Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.Developing an effective breast cancer vaccine.Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma.Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance.Metastatic melanoma cells evade immune detection by silencing STAT1.YB-1 immunization combined with regulatory T-cell depletion induces specific T-cell responses that protect against neuroblastoma in the early stage.Foxp3 expression in melanoma cells as a possible mechanism of resistance to immune destruction.Overall survival and PD-L1 expression in metastasized malignant melanoma.Antigenic stimulation with cytochrome P450 2J expressed in mouse hepatocellular carcinoma cells regulates host anti-tumour immunity.Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B.cGAS-STING Activation in the Tumor Microenvironment and Its Role in Cancer Immunity.Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes.Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer.Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice.
P2860
Q26865532-3DD8B084-4B33-4AD4-94AD-F2E59807477CQ33593858-681B9B0A-40C1-4C3E-BF3A-9D8EDC22335BQ33649569-96DD1E6D-7E84-47BA-AE4E-477CC03A333EQ34606735-FD6299CA-7772-4FCD-9FFE-72BB05AFC59FQ34880391-CCDF1B9C-8D2F-433B-97E7-3684993FD052Q35263440-269DC7C9-DFC0-4419-9AC3-1A84E50B8B63Q35598991-789D1806-BD69-42AB-81D5-B555EA01270BQ35871717-7A95CECD-B641-4843-8A94-EEF10E3ED2D5Q36184314-CA83388B-E3E4-4F47-9656-4532B7C86EC7Q36243536-7A4BC58E-01B3-4926-B593-70E03F247C3CQ36259633-804A5049-5DB6-40B0-A897-A72191B608F2Q36443331-5CD6FA02-A08F-498A-8307-2C5246BA0F90Q36447564-41791B1F-F98E-4DCB-A4F0-62CB19F52265Q36476449-46F76934-21B5-4783-A755-1626394411DEQ36784048-6581D296-549D-4C8A-A096-5A644DDFAFD6Q37114128-08F2F674-6366-45B7-AF55-FFC6F01AABA4Q37336918-8B7A1540-FCF2-4F20-A855-B04518E51E94Q37513109-BB0F5D19-C770-4BC6-89FA-33E079B5AED2Q37776145-D0CE9CC5-0261-485A-8778-4FEFE9B567E5Q37801939-1D738686-E499-4EE7-A253-AA46C10E1295Q37836612-A7AE1CD5-B579-4A87-B595-B1CB0E318928Q38908693-D0E4C930-3BC9-422F-B10C-61842A9DE366Q39241485-9440893F-1630-459C-83A3-446F04517096Q39547224-52B04E64-A47B-414C-833B-AA7BA3631DCDQ39756798-A758B375-2D4C-4EA1-9E79-3B146D5BE9D8Q39870340-FD6E1EDA-C8C6-45EF-8A58-01A0EB965DECQ40088374-3C8F8A9C-FAEB-4A36-8E87-6F836BA743C8Q41997059-2D89EBCD-D010-4868-839F-967BD301E76FQ43800437-FA8A62D5-1C3F-43EF-9D8B-A57721875D3BQ48120429-12DF74F0-E0E8-4059-B6B1-68398E1D40C1Q53394735-7AFB11C4-6CA4-4376-BAF8-09A13C7E50A3
P2860
Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Identifying and overcoming imm ...... lanoma tumor microenvironment.
@ast
Identifying and overcoming imm ...... lanoma tumor microenvironment.
@en
type
label
Identifying and overcoming imm ...... lanoma tumor microenvironment.
@ast
Identifying and overcoming imm ...... lanoma tumor microenvironment.
@en
prefLabel
Identifying and overcoming imm ...... lanoma tumor microenvironment.
@ast
Identifying and overcoming imm ...... lanoma tumor microenvironment.
@en
P1476
Identifying and overcoming imm ...... lanoma tumor microenvironment.
@en
P2093
Thomas F Gajewski
P304
2326s-2330s
P356
10.1158/1078-0432.CCR-05-2517
P407
P433
P577
2006-04-01T00:00:00Z